NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ACUTAAS · data 2026-10-30
Acutaas Chemicals Ltd
In plain words
Price: at or near its 52-week high.
Delivery: 40.7% of traded shares were kept for delivery over the last 10 sessions, against 49.5% over the last 60.
Latest results: a net profit of ₹45 cr for the quarter ended Dec 2024.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹1,593 cr |
| Net profit (last 12 months) | ₹439 cr |
| Sales growth, 3 years (yearly) | 29.5% |
| Profit growth, 3 years (yearly) | 62.3% |
Latest results in brief (Q2 FY27)
ACUTAAS Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹436.92 crore, up 42.7% YoY and up 32.5% QoQ.
Net profit was ₹125.17 crore, up 73.3% YoY and up 68.6% QoQ.
Operating margin was 40.3% (31.1% a year ago).
EPS was ₹15.29, up 73.4% YoY and up 68.6% QoQ.
ACUTAAS के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹436.92 करोड़; पिछले साल की तुलना में 42.7% की बढ़त, पिछली तिमाही की तुलना में 32.5% की बढ़त।
शुद्ध मुनाफ़ा: ₹125.17 करोड़; पिछले साल की तुलना में 73.3% की बढ़त, पिछली तिमाही की तुलना में 68.6% की बढ़त।
ऑपरेटिंग मार्जिन: 40.3% (एक साल पहले 31.1%)।
EPS: ₹15.29; पिछले साल की तुलना में 73.4% की बढ़त, पिछली तिमाही की तुलना में 68.6% की बढ़त।
ACUTAASના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹436.92 કરોડ; ગયા વર્ષની સરખામણીએ 42.7% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 32.5% વધારો.
ચોખ્ખો નફો: ₹125.17 કરોડ; ગયા વર્ષની સરખામણીએ 73.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 68.6% વધારો.
ઓપરેટિંગ માર્જિન: 40.3% (એક વર્ષ પહેલાં 31.1%).
EPS: ₹15.29; ગયા વર્ષની સરખામણીએ 73.4% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 68.6% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
41/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 13/30: Delivery 34.2% over the last 20 sessions vs 49.8% in the 40 before (0.69x); shares delivered per day 1.94x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 9/15: 15 schemes hold it, about ₹673 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 14/15: Verdict "Sustained", sustained score 92/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend ● Split
- 27 Oct 26Results Q2 FY27 results: profit +73.3% YoY +10.8% next session
- 17 Sept 26Dividend Dividend ₹2.5 (ex-date) +2.9% next session
- 24 Jul 26Results Q1 FY27 results: profit +67.7% YoY -2.6% next session
- 30 Apr 26Results Q4 FY26 results: profit +110.9% YoY +7.0% next session
- 28 Jan 26Results Q3 FY26 results: profit +140.2% YoY +11.9% next session
- 17 Oct 25Results Q2 FY26 results: profit +93.5% YoY +13.5% next session
- 18 Sept 25Dividend Dividend ₹1.5 (ex-date) -1.1% next session
- 30 Jul 25Results Q1 FY26 results: profit +217.5% YoY +13.7% next session
- 2 May 25Results Q4 FY25 results: profit +148.4% YoY +6.3% next session
- 25 Apr 25Split Split: face value ₹10 → ₹5 (ex-date)
- 29 Jan 25Results Q3 FY25 results: profit +168.4% YoY
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Dec 2024 | ₹275 cr | ₹45 cr | — | 25.0% | 11.35 |
| Mar 2024 | ₹225 cr | ₹25 cr | — | 19.2% | 6.86 |
Shareholding trend
| Holder | Mar 2025 |
|---|---|
| Promoters | 35.96% |
| Foreign institutions (FII) | 16.48% |
| Domestic institutions (DII) | 18.31% |
| Mutual funds | 13.02% |
| Retail investors | 14.89% |
| Number of shareholders | 1,14,060 |
Common questions
What was Acutaas Chemicals Ltd's latest quarterly profit?
Acutaas Chemicals Ltd reported a net profit of ₹45 cr for the quarter ended Dec 2024, on revenue of ₹275 cr.
How much do promoters hold in Acutaas Chemicals Ltd?
Promoters held 35.96% of Acutaas Chemicals Ltd at the end of Mar 2025, with 0.00% of promoter shares pledged.
Is Acutaas Chemicals Ltd debt-free?
Its latest reported debt-to-equity ratio is 0.02, which is very low.
What is Acutaas Chemicals Ltd's P/E ratio?
About 75, based on the last 12 months' earnings and a price of ₹4,003.6 (data 2026-10-30).
What is the 52-week high and low of Acutaas Chemicals Ltd?
The 52-week high is ₹4,032.2 and the 52-week low is ₹1,570.
Mutual funds holding Acutaas Chemicals Ltd
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 15 schemes holding about ₹673 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 5.03% | ₹295 cr |
| SBI Smallcap Fund | SBI Mutual Fund | 0.30% | ₹123 cr |
| ADITYA BIRLA SUN LIFE SMALL CAP FUND | Aditya Birla Sun Life Mutual Fund | 1.32% | ₹81 cr |
| SBI Innovative Opportunities Fund | SBI Mutual Fund | 0.90% | ₹46 cr |
| SBI Quality Fund | SBI Mutual Fund | 1.02% | ₹26 cr |
| Nippon India Nifty Smallcap 250 Index Fund | Nippon India Mutual Fund | 0.76% | ₹26 cr |
| Mirae Asset Nifty Smallcap 250 Momentum Quality 100 ETF | Mirae Asset Mutual Fund | 2.80% | ₹26 cr |
| Nippon India Nifty 500 Momentum 50 Index Fund | Nippon India Mutual Fund | 1.47% | ₹19 cr |
| SBI Nifty Smallcap 250 Index Fund | SBI Mutual Fund | 0.76% | ₹13 cr |
| ADITYA BIRLA SUN LIFE NIFTY SMALLCAP 50 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 2.00% | ₹7 cr |
| Mirae Asset Nifty MidSmallcap400 Momentum Quality 100 ETF | Mirae Asset Mutual Fund | 1.53% | ₹7 cr |
| ADITYA BIRLA SUN LIFE BSE 500 MOMENTUM 50 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 1.15% | ₹1 cr |
| Mirae Asset Nifty Smallcap 250 ETF | Mirae Asset Mutual Fund | 0.76% | ₹1 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 1.26% | ₹0 cr |
| SBI Nifty Small Cap 250 ETF | SBI Mutual Fund | 0.76% | ₹0 cr |
Similar companies
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) · Emcure Pharmaceuticals Limited (EMCURE) · Wockhardt Limited (WOCKPHARMA) · Piramal Pharma Limited (PPLPHARMA) · Neuland Laboratories Ltd. (NEULANDLAB)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ACUTAAS in NSE Scanner →